Eli Lilly and Company balance sheet
At the end of its fiscal year on Dec 31, 2025, Eli Lilly and Company reported total assets of $112.48B and shareholders' equity of $26.54B. That works out to a current ratio of 1.58 (current assets ÷ current liabilities), long-term debt of 1.54× shareholders' equity.
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $38.81B | $44.98B | $43.91B | $39.29B | $46.63B | $48.81B | $49.49B | $64.01B | $78.72B | $112.48B |
| Current assets | $15.10B | $19.20B | $20.55B | $13.71B | $17.46B | $18.45B | $18.03B | $25.73B | $32.74B | $55.63B |
| Cash & equivalents | $4.58B | $6.54B | $7.32B | $2.34B | $3.66B | $3.82B | $2.07B | $2.82B | $3.27B | $7.27B |
| Current liabilities | $10.99B | $14.54B | $11.89B | $11.78B | $12.48B | $15.05B | $17.14B | $27.29B | $28.38B | $35.23B |
| Long-term debt | $8.37B | $9.94B | $9.20B | $13.82B | $16.59B | $15.35B | $14.74B | $18.32B | $28.53B | $40.87B |
| Shareholders' equity | $14.01B | $11.59B | $9.83B | $2.61B | $5.64B | $8.98B | $10.65B | $10.77B | $14.27B | $26.54B |
| Reported in | 10-K 2018 | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 59478 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.